IT-based programs can improve cardiovascular disease management and patient empowerment, but must be accompanied by supportive social and political environments and active patient and clinician engagement, according to an article published online Aug. 24 in PLoS Medicine.
Whole-body FDG-PET scans revealed that visceral adipose tissue has increased glucose uptake compared with subcutaneous adipose tissue and the differences in stromal metabolic activity can aid in cardiovascular risk stratification, according to a study published in this month’s Journal of American College of Cardiology: Cardiovascular Imaging.
Ultrasound developer SonoSite has named Marcus Smith as its new chief financial officer and senior vice president, following the retirement of Mike Schuh.
Along with an increased risk of mortality, pediatric patients who survive childhood cancer may also have have an increased risk of long-term abnormal cardiac function, according to a study published July 26 in the Archives of Internal Medicine.
The estimated glomerular filtration rate, which represents renal function, might play an important role in identifying high-risk diabetic persons who would benefit most from myocardial perfusion imaging by SPECT for suspected ischemia, according to a study published in this month's Journal of the American College of Cardiology: Cardiovascular Imaging.
Written by Manjula Puthenedam
Cardiac imaging procedures represent an important source of ionizing radiation in the U.S., and the distribution of cumulative effective doses can lead to sizable radiation exposure for many individuals, according to a study published online July 7 in the Journal of the American College of Cardiology. Better strategies to minimize the radiation exposure from cardiac imaging procedures should be encouraged, said the study's lead author Jersey Chen, MD, in an interview.
St. Jude Medical has completed the previously announced acquisition of LightLab Imaging, a former Goodman subsidiary, for approximately $90 million in cash.
Women presenting with either obesity alone or in the presence of metabolic syndrome have high rates of abnormal ultrasound findings, despite being identified as low risk by traditional risk assessment tools, according to the results of the HAPPY Heart trial presented at the American Society of Echocardiography (ASE) 21st Annual Scientific Sessions in San Diego this week.
Royal Philips Electronics and RXi Pharmaceuticals, a biopharmaceutical company, have entered into a joint research agreement to combine the proprietary technologies from both companies to explore the targeted delivery of experimental therapeutics based on RNA interference (RNAi).
GE Healthcare and CardioDx, a cardiovascular genomic diagnostics company, have entered into a strategic alliance to co-develop diagnostic technologies to improve the care and management of patients with cardiovascular disease.
Previously, patient radiation exposure from CT scans were compared to similar doses of radiation received by Hiroshima atomic bomb survivors. Today, with a push for dose reduction technology to hamper these concerns, dose exposure has significantly decreased, but fears still remain.
U.S. Vice President Joseph Biden and Health and Human Services Secretary Kathleen Sebelius have selected 15 pilot communities for wide-scale use of health IT through the Beacon Community program, with awards totaling $220 million from the American Recovery and Reinvestment Act.
The use of a coronary artery calcium (CAC) score in addition to traditional risk factors was determined to be associated with improved prediction of heart disease risk, and placed more individuals in the most extreme risk categories, said a study published April 28 in the Journal of the American Medical Association.
Cardiovascular and metabolic disease biotechnology company Via Pharmaceuticals has launched a strategic restructuring and financing of its resources related to research and development of its line of drug candidates, beginning with a workforce reduction and a $1.25 million draw from a new $3 million secured Note and Warrant Purchase Agreement with the company's principal stockholder.
Written by Gina Narcisi
QATLANTA - Originally piloted two years ago as the Improving Continuous Cardiac Care IC3 registry, the recently rebranded PINNACLE registry is the first and only ambulatory registry for cardiovascular conditions in this country, noted William Oetgen, MD, clinical associate professor of medicine at Georgetown University, at the 59th annual American College of Cardiology (ACC) annual conference on March 16.
Interventional radiologists have found that a subgroup of patients with critical limb ischemia, the most severe form of peripheral arterial disease (PAD), may avoid amputation through the use of drug-eluting stents on the smaller arteries below the knee, according to a study released at this week’s Society of Interventional Radiology's (SIR) Annual Scientific Meeting in Tampa, Fla.
Testing patients for peripheral arterial disease (PAD) via abnormal ankle brachial index (ABI) exams can identify patients at risk for future cardiac events who were not considered in the high-risk category with Framingham risk assessments, according to results of a clinical trial presented at the 35th annual scientific meeting of the Society of Interventional Radiology's in Tampa, Fla.
Pennsylvania-based biotechnology company Molecular Targeting Technologies has obtained a license from the University of Notre Dame for a novel sensing technology developed by Bradley Smith, PhD, Emil T. Hofman professor of chemistry and biochemistry, University of Notre Dame, that images cell death.
Royal Philips Electronics of the Netherlands and the VU University Medical Center, Amsterdam, the Netherlands have signed an agreement to jointly research new multimodality imaging solutions aimed at improving the early detection and treatment of cancer and neurological and cardiovascular diseases.
Researchers at Massachusetts Institute of Technology and Harvard Medical School have built targeted nanoparticles that can cling to artery walls and slowly release medicine, which could be an alternative to drug-eluting stents in some patients with cardiovascular disease, according to research published in the Jan. 18 issue of the Proceedings of the National Academy of Sciences.
|